CLAIMS

1. The use of a pharmaceutical composition comprising:

Eicosapentaenoic acid (EPA) in a weight percent amount of 50% to 60%;

Docosahexaenoic acid (DHA) in a weight percent amount of 17% to 23%;

Docosapentaenoic acid (n-3)(DPA) in a weight percent amount of 1% to 8%;

wherein at least 90% by weight of the polyunsaturated acid in the composition is present in the free acid form, in the manufacture of a medicament for the treatment of hypertriglyceridemia, wherein the treatment, once started, comprises the oral administration of at least about 2g per day of the pharmaceutical composition to a patient on statin therapy having pre-treatment serum or plasma triglyceride levels of 200 mg/dL to 500 mg/dL.

2. The use according to claim 1, wherein the amount of pharmaceutical composition is at least about 3g per day.

3. The use according to claim 1, wherein the amount of pharmaceutical composition is at least about 4g per day.

4. The use according to any one of claims 1-3, wherein at least 95% by weight of the polyunsaturated fatty acid in the composition is present in the free acid form.

5. The use according to any one of claims 1-3, wherein DPA is present in a weight percent amount of at least about 2%.

6. The use according to any one of claims 1-3, wherein DPA is present in a weight percent amount of at least about 3%.

7. The use according to any one of claims 1-3, wherein DPA is present in a weight percent amount of at least about 4%.

8. The use according to any one of claims 1-3, wherein DPA is present in a weight percent amount of at least about 4.5%.

9. The use according to any one of claims 1-3, wherein the pharmaceutical composition comprises EPA present in a weight percent amount of about 55% to about 56%; DHA present in a weight percent amount of about 19% to about 20%; DPA present in a weight percent amount of about 4% to about 5%.